medigraphic.com
SPANISH

Revista de Enfermedades no Transmisibles Finlay

ISSN 2221-2434 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 2

<< Back Next >>

Finlay 2019; 9 (2)

Leuko-glycemic index as a prognostic factor after acute myocardial infarction with ST-segment elevation

Rodríguez JA, Fardales RR, Toledo RE, Quintana CG
Full text How to cite this article

Language: Spanish
References: 22
Page: 97-107
PDF size: 437.42 Kb.


Key words:

leukocyte count, blood glucose, prognosis, st elevation myocardial infarction.

ABSTRACT

Foundation: blood glucose and leukocyte count at admission have shown prognostic significance in patients with myocardial infarction. Leuko-glycemic index is a recently proposed marker as a predictor of mortality.
Objective: to evaluate the usefulness of the leuko-glycemic index in the stratification of the risk of in-hospital death after STEMI.
Method: a prospective observational study was conducted which included all patients admitted consecutively with a diagnosis of acute myocardial infarction with ST segment elevation and Killip> I class, from January 2012 to June 2015 at the Provincial University Hospital Camilo Cienfuegos Gorriarán. Clinical, laboratory and echocardiographic data were collected and the prognostic implication of the leuko-glycemic index in in-hospital mortality was determined through binary logistic regression. The studied variables were: age, sex and color of the skin, medical history and cardiovascular risk factors, clinical data such as systolic and diastolic blood pressure as well as heart rate at admission.
Results: LGI was a predictor of mortality in both diabetic and non-diabetic patients (c = 0.673 and c = 0.707) respectively. There was a positive correlation between the Killip class and the leuco-glycemic index (r: 0.471 p <0.001). The 75th percentile showed an acceptable sensitivity and good specificity as a predictor of complications and mortality after STEMI.
Conclusions: the leuko-glycemic index in the course of an acute myocardial infarction can be associated with a higher in-hospital mortality. Its detection would be useful in the prognostic stratification of acute coronary syndrome.


REFERENCES

  1. Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli C, Bueno H, et al. Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Rev Esp Cardiol [revista en Internet]. 2017 [citado 23 Oct 2018];70(12):[aprox. 6p]. Disponible en: http://www.revespcardiol.org/es/guia-esc-2017-sobre-el/articulo/90461843/ [Buscar en Google Scholar]

  2. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-64 [Buscar en Google Scholar]

  3. Ministerio de Salud Pública. Anuario Estadístico de Salud 2017 [Internet]. La Habana: Dirección Nacional de Estadísticas; 2018 [citado 5 Ene 2019]. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Español-2017-ed-2018.pdf [Buscar en Google Scholar]

  4. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82(1):1-27 [Buscar en Google Scholar]

  5. Shiyovich A, Gilutz H, Plakht Y. White Blood Cell Subtypes Are Associated with a Greater Long-Term Risk of Death after Acute Myocardial Infarction. Tex Heart Inst J. 2017;44(3):176-88 [Buscar en Google Scholar]

  6. Millard RW, Tranter M. Biomarcadores no troponínicos, complementarios, alternativos y presuntos, para el síndrome coronario agudo: nuevos recursos para los futuros instrumentos de cálculo del riesgo. Rev Esp Cardiol [revista en Internet]. 2014 [citado 24 Oct 2018];67(4):[aprox. 8p]. Disponible en: http://www.revespcardiol.org/es/biomarcadores-no-troponinicos-complementarios-alternativos/articulo-resumen/90283557/ [Buscar en Google Scholar]

  7. León E, Moreno FL, Pérez GA, Vega LF, Rabassa MA. Índice leuco-glucémico como marcador pronóstico de la evolución intrahospitalaria en pacientes con infarto agudo de miocardio con elevación del ST. Clin Invest Arterioscl. 2014;26(4):159-204 [Buscar en Google Scholar]

  8. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017;10(9):e004981 [Buscar en Google Scholar]

  9. Martins H, Monteiro S, Goncalves F, Monteiro P, Pego M. Glucemia en los síndromes coronarios agudos. ¿Hasta qué nivel debe reducirse?. Rev Esp Cardiol [revista en Internet]. 2015 [citado 2 Feb 2017];68(1):[aprox. 5p]. Disponible en: https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0300893214002152.pdf?locale=es_ES&searchIndex [Buscar en Google Scholar]

  10. Gómez D, Sánchez G, Pérez M, García RG, Arguello JF, Peñaherrera E, et al. Hiperglucemia se asocia a mayor número de desenlaces adversos en individuos latinoamericanos con infarto agudo de miocardio. Clin Invest Arterioscl [revista en Internet]. 2016 [citado 23 Oct 2018];28(1):[aprox. 9p]. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0214916815001291 [Buscar en Google Scholar]

  11. Cabrerizo JL, Gimeno JA, Zalba B, Pérez JI. La hiperglucemia como factor de mal pronóstico en el síndrome coronario agudo. Rev Clin Esp [revista en Internet]. 2011 [citado 12 Ene 2018];211(6):[aprox. 3p]. Disponible en: https://www.revclinesp.es/es-la-hiperglucemia-como-factor-mal-articulo-S0014256511001135 [Buscar en Google Scholar]

  12. Quiroga W, Conci E, Zelaya F, Isa M, Pacheco G, Sala J, et al. Estratificación del riesgo en el infarto agudo de miocardio según el índice leucoglucémico. ¿El Killip-Kimball de laboratorio?. Rev Fed Arg Cardiol [revista en Internet]. 2010 [citado 23 Feb 2018];39(1):[aprox. 5p]. Disponible en: http://www.fac.org.ar/1/revista/10v39n1/art_orig/arorig01/quiroga.pdf [Buscar en Google Scholar]

  13. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):618-51 [Buscar en Google Scholar]

  14. Bayés de Luna A. Bases de la electrocardiografía. De las variantes de la normalidad a los patrones diagnósticos (III): Isquemia, lesión y necrosis. Barcelona: Prous Science; 2007 [Buscar en Google Scholar]

  15. Górriz JL, Beltrán S. Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Rev Esp Cardiol [revista en Internet]. 2011 [citado 24 Nov 2018];64(12):[aprox. 10p]. Disponible en: http://www.revespcardiol.org/es/valoracion-afeccion-renal-disfuncion-renal/articulo/S0300893211007743/ [Buscar en Google Scholar]

  16. Bedetti G, Gargani L, Sicari R, Gianfaldoni ML, Molinaro S, Picano E. Comparison of Prognostic Value of Echocardiacgraphic Risk Score With the Thrombolysis In Myocardial Infarction (TIMI) and Global Registry In Acute Coronary Events (GRACE) Risk Scores in Acute Coronary Syndrome. Am J Cardiol. 2010;106(12):1709-16 [Buscar en Google Scholar]

  17. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Del Pinto M, Repaci S, et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr Diabetes Rev. 2010;6(2):102-10 [Buscar en Google Scholar]

  18. Monteiro S, Monteiro P, Goncalves F, Freitas M, Providencia LA. Hyperglycaemia at admission in acute coronary syndrome patients: prognostic value in diabetics and non-diabetics. Eur J Cardiovasc Prev Rehabil. 2010;17(2):155-9 [Buscar en Google Scholar]

  19. García Y, González CM, Jorrín FR, Valladares FJ, Navarro JJ, Castillo S. Hiperglicemia, marcador pronóstico de eventos adversos en el infarto agudo de miocardio. Rev Cubana Cardiol Cir Cardiovasc [revista en Internet]. 2014 [citado Jun 11];19(2):[aprox. 6p]. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/342 [Buscar en Google Scholar]

  20. Lee TF, Burt MG, Heilbronn LK, Mangoni AA, Wong VW, McLean M, et al. Relative hyperglycemia is associated with complications following an acute myocardial infarction: a post‑hoc analysis of HI‑5 data. Cardiovasc Diabetol. 2017;16(1):157 [Buscar en Google Scholar]

  21. Liang Y, Chen H, Wang P. Correlation of Leukocyte and Coronary Lesion Severity of Acute Myocardial Infarction. Angiology. 2018;69(7):591-9 [Buscar en Google Scholar]

  22. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, et al. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: Analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007;28(7):806-13




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Finlay. 2019;9